C. Droege

A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer

Miklos Pless, C. Droege, Roger von Moos et al. · Lung Cancer · 2013 · 101 citations

Tumor Treating Fields, Medicine, Bronchial Neoplasm +8

Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment

B.H.M. Lenfers, Tina Loeffler, C. Droege et al. · Annals of Oncology · 1999 · 74 citations

Gastrointestinal Pharmacology, Medicine, Loperamide Treatment +6

Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)

Richard Cathomas, Christian Rothermundt, Dirk Klingbiel et al. · Clinical Cancer Research · 2012 · 45 citations

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)

Markus Joerger, Florent Baty, Martin Früh et al. · Lung Cancer · 2014 · 42 citations

Microrna Profiling, Sakk 19/05, Medicine +9

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

Francesco Zappa, C. Droege, Daniel Betticher et al. · Lung Cancer · 2012 · 32 citations

First-line Therapy, Sakk 19/05, Medicine +8